SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, DC 20549

                                FORM 12b-25

                        Commission File Number 000-07405


                           NOTIFICATION OF LATE FILING


(Check One):  [_] Form  10-K   [_] Form 11-K   [_] Form 20-F   [X] Form 10-Q
              [_] Form N-SAR

                      For Period Ended: November 30, 2004


[_] Transition Report on Form 10-K

[_] Transition Report on Form 20-F

[_] Transition Report on Form 11-K

[X] Transition Report on Form 10-Q

[_] Transition Report on Form N-SAR


    For the Transition Period Ended: November 30, 2004

     Read attached instruction sheet before preparing form. Please print or
type. Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:


                                     PART I
                             REGISTRANT INFORMATION


Mediscience Technology Corp.
- --------------------------------------------------------------------------------
Full name of registrant

Cardiac Techniques Inc.
- --------------------------------------------------------------------------------
Former name if applicable

1235 Folkestone Way
- --------------------------------------------------------------------------------
Address of principal executive office (Street/ No.)

Cherry Hill, New Jersey 08034
- --------------------------------------------------------------------------------
City, state and zip code













                                     PART II
                             RULE 12b-25(b) AND (c)




     If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)

[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form
10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15th calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and


[_](c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.

                                    PART III
                                    NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed.)

     The Registrant was unable to file the Form 10-QSB for the quarter ended
November 30, 2004(the "Report") without unreasonable effort or expense due to
the related delays in gathering information for inclusion in the Report
associated therewith.

                                     PART IV
                                OTHER INFORMATION

     (1) Name and telephone number of person to contact in regard to this
notification

    Peter Katevatis:             (856)                   428-7952
- --------------------------------------------------------------------------------
        (Name)                (Area Code)            (Telephone number)







     (2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). [X] Yes [_] No


     (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? [_]
Yes [X] No

     If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.


                          Mediscience Technology Corp.
- --------------------------------------------------------------------------------
                  (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized:

Date January 12,2005                            /s/ Peter Katevatis
                                                -------------------------
                                         Name:  Peter Katevatis
                                         Title: Chairman of the Board and
                                                Chief Executive Officer

     Instruction. The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.

                                    ATTENTION

Intentional misstatements or omissions of fact constitute Federal criminal
violations.(See 18 U.S.C. 1001).